VC

Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the threat of bacterial diseases. The company utilizes its proprietary XpressCF cell-free protein synthesis platform to design and produce complex conjugate vaccines that aim to provide broader protection than existing standards of care. Vaxcyte's lead program, VAX-31, is a 31-valent pneumococcal conjugate vaccine (PCV) currently in Phase 3 development, designed to address the evolving epidemiology of pneumococcal disease. Beyond its pneumococcal franchise, the company is advancing a pipeline of candidates targeting Group A Strep, periodontitis, and Shigella.